Ingredients: Analysis of active ingredients, intermediates, and excipients in pharmaceutical development and manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ingredients
Trends, market analysis, and market growth reports on pharmaceutical ingredient suppliers and manufacturers. Sourcing and supply of active pharmaceutical ingredients (APIs), intermediates, excipients.

Risk Reduction Top Driver for Biopharmaceutical Raw Material Development

August 2, 2014

Pharmaceutical Technology

Customers are looking to reduce risk, increase performance, and optimize productivity.

How Excipient Supplier Certification Helps Pharmaceutical Supply Chain in Europe

August 1, 2014

Pharmaceutical Technology Europe

The EXCiPACT Certification Scheme ensures patient safety through supplier quality while minimising the audit burden and overall costs for assessing the excipient supply chain.

Supply-Chain Security of Pharmaceutical Starting Materials

August 1, 2014

Pharmaceutical Technology Europe

IPEC Europe continues to promote the quality, safety and functionality of excipients used in pharmaceutical products.

The Mainstreaming of Continuous Flow API Synthesis

July 2, 2014

Pharmaceutical Technology

The pharma industry is moving toward commercial-scale continuous processes for small-molecule API manufacturing.

Seeking Alternative Catalyst Solutions

June 2, 2014

Pharmaceutical Technology

Transition metal-containing catalysts are widely used in organic synthesis, but many are based on expensive, rare metals. Researchers are seeking more sustainable alternatives.

HPAPIs: Fast-growing Segment Presents Challenges and Opportunities

May 30, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

Appropriate process design and engineering are critical for the production of small-molecule and biologic HPAPIs.

BPTF Warns FDA on Reduced API Manufacturer Inspections

May 29, 2014
PTSM: Pharmaceutical Technology Sourcing and Management

The Bulk Pharmaceuticals Task Force asks FDA to respond to concerns about reduction in API facility compliance inspections.

Control Strategies for Synthetic Therapeutic Peptide APIs Part III: Manufacturing Process Considerations

May 2, 2014

Pharmaceutical Technology

USP's Therapeutic Peptides Expert Panel discusses manufacturing processes and impurity control for synthetic peptide APIs.

Scientific Advances in Cocrystals are Offset by Regulatory Uncertainty

May 2, 2014

Pharmaceutical Technology

Drug developers are taking a wait-and-see approach to the use of cocrystals.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here